| Current Price | $9.64 | Mkt Cap | $11.8B |
|---|---|---|---|
| Open | $9.69 | P/E Ratio | 6.32 |
| Prev. Close | $9.64 | Div. (Yield) | $0.48 (5.0%) |
| Daily Range | $9.57 - $9.73 | Volume | 6,150,472 |
| 52-Wk Range | $8.42 - $12.40 | Avg. Daily Vol. | 8,452,337 |
The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.
| Current Price | $9.64 | Mkt Cap | $11.8B |
|---|---|---|---|
| Open | $9.69 | P/E Ratio | 6.32 |
| Prev. Close | $9.64 | Div. (Yield) | $0.48 (5.0%) |
| Daily Range | $9.57 - $9.73 | Volume | 6,150,472 |
| 52-Wk Range | $8.42 - $12.40 | Avg. Daily Vol. | 8,452,337 |
The best Bull and Bear pitches based on recency and number of recommendations.
continued improving earnings as patents expired for big pharma
Mylan is known for making good quality, reliable generic pharmaceutical products, but I think their primary drawback is they haven't found a way to outcompete the generic market. In the pharmacy, cheaper generics are preferred to Mylan's oftentimes… More
Read the most recent pitches from players about VTRS.
Recs
Foolishwisegirl1
(< 20)
Submitted: 5/9/2022 11:09:12 AM :
Start Price:
$9.88
NASDAQ:VTRS Score:
-9.51
Why is this a great stock?
Recs
JTPigskin
(< 20)
Submitted: 3/18/2022 5:42:48 AM :
Start Price:
$9.32
NASDAQ:VTRS Score:
-0.85
Push for cheaper and generic drugs will drive their sales
Recs
TMFkodyk123
(45.69)
Submitted: 7/30/2021 2:22:42 PM :
Start Price:
$12.98
NASDAQ:VTRS Score:
-23.89
The FDA's approval of Viatris and Biocon's Lantus insulin biosimilar, Semglee, will reach countless Americans and generate a couple hundred million dollars in annual revenue. More importantly, the FDA's approval is an indication of things to come as it relates to biosimilars, which should be big business for Viatris.
Find the members with the highest scoring picks in VTRS.
heftyjeffy (< 20) Score: +425.23
The Score Leader is the player with the highest score across all their picks in VTRS.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| heftyjeffy | < 20 | 1/26/2009 |
|
1Y | $9.77 | -1.24% | +424.00% | +425.23 | 0 Comment | |
| SpecBull | 74.29 |
|
|
3W | $12.10 | -20.31% | +397.40% | +417.71 | 0 Comment | |
| alley11 | < 20 | 5/1/2009 |
|
3W | $12.10 | -20.31% | +397.40% | +417.71 | 0 Comment | |
| GenericMike | 23.06 | 7/10/2009 |
|
3M | $11.02 | -12.52% | +392.24% | +404.76 | 0 Comment | |
| wcwhiner | 27.25 | 7/23/2009 |
|
5Y | $12.16 | -20.67% | +341.87% | +362.54 | 0 Comment | |
| aguacer0 | 40.70 | 7/28/2009 |
|
3W | $11.50 | -16.10% | +341.50% | +357.61 | 0 Comment | |
| Spelunkin | 25.86 | 11/5/2009 |
|
5Y | $15.40 | -37.37% | +307.36% | +344.74 | 0 Comment | |
| TrackDuality | < 20 | 11/6/2009 |
|
5Y | $15.65 | -38.39% | +305.06% | +343.45 | 0 Comment | |
| GoodbyeForNow | 98.41 | 10/8/2009 |
|
5Y | $15.17 | -36.44% | +303.96% | +340.40 | 0 Comment | |
| TrackCarter | 23.23 | 9/21/2009 |
|
3M | $14.43 | -33.17% | +306.48% | +339.64 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
